Simplify Asset Management Inc. Sells 44,496 Shares of Abivax SA Sponsored ADR $ABVX

Simplify Asset Management Inc. decreased its holdings in shares of Abivax SA Sponsored ADR (NASDAQ:ABVX) by 72.4% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 16,953 shares of the company’s stock after selling 44,496 shares during the quarter. Simplify Asset Management Inc.’s holdings in Abivax were worth $2,286,000 as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in ABVX. EverSource Wealth Advisors LLC boosted its holdings in Abivax by 4,612.5% during the third quarter. EverSource Wealth Advisors LLC now owns 377 shares of the company’s stock worth $32,000 after purchasing an additional 369 shares during the last quarter. Bank of America Corp DE boosted its holdings in Abivax by 56.1% during the fourth quarter. Bank of America Corp DE now owns 5,536 shares of the company’s stock worth $41,000 after purchasing an additional 1,990 shares during the last quarter. Hantz Financial Services Inc. acquired a new position in Abivax during the third quarter worth $52,000. WPG Advisers LLC boosted its holdings in Abivax by 125.9% during the fourth quarter. WPG Advisers LLC now owns 454 shares of the company’s stock worth $61,000 after purchasing an additional 253 shares during the last quarter. Finally, Cubist Systematic Strategies LLC boosted its holdings in Abivax by 34.3% during the first quarter. Cubist Systematic Strategies LLC now owns 10,152 shares of the company’s stock worth $63,000 after purchasing an additional 2,595 shares during the last quarter. Institutional investors and hedge funds own 47.91% of the company’s stock.

Abivax Stock Performance

NASDAQ:ABVX opened at $121.99 on Monday. Abivax SA Sponsored ADR has a 52 week low of $5.59 and a 52 week high of $148.83. The firm has a market cap of $9.72 billion, a price-to-earnings ratio of -23.41 and a beta of 0.84. The firm’s 50-day simple moving average is $117.74 and its 200 day simple moving average is $119.12.

Abivax (NASDAQ:ABVX) last released its earnings results on Friday, May 22nd. The company reported ($0.71) EPS for the quarter, beating the consensus estimate of ($0.94) by $0.23. The firm had revenue of $1.56 million during the quarter, compared to the consensus estimate of $0.40 million. Sell-side analysts anticipate that Abivax SA Sponsored ADR will post -3.84 EPS for the current year.

Analysts Set New Price Targets

Several research analysts recently commented on the stock. Barclays increased their target price on shares of Abivax from $142.00 to $148.00 and gave the stock an “overweight” rating in a report on Tuesday, March 24th. Weiss Ratings restated a “sell (d-)” rating on shares of Abivax in a report on Monday, April 20th. Jefferies Financial Group began coverage on shares of Abivax in a research note on Monday, March 16th. They issued a “buy” rating and a $160.00 price target for the company. Wall Street Zen upgraded shares of Abivax from a “sell” rating to a “hold” rating in a research note on Saturday. Finally, BTIG Research reiterated a “buy” rating and issued a $150.00 price target on shares of Abivax in a research note on Wednesday, February 25th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $137.15.

About Abivax

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.